Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain

BACKGROUND: Detection of the ROS1 rearrangement is mandatory in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to allow targeted therapy with specific inhibitors. However, in Spanish clinical practice ROS1 determination is not yet fully widespread. The aim of this study is t...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojo, Federico, Conde, Esther, Torres, Héctor, Cabezón-Gutiérrez, Luis, Bautista, Dolores, Ramos, Inmaculada, Carcedo, David, Arrabal, Natalia, García, J. Francisco, Galán, Raquel, Nadal, Ernest
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933896/
https://www.ncbi.nlm.nih.gov/pubmed/35303812
http://dx.doi.org/10.1186/s12885-022-09397-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933896/
https://www.ncbi.nlm.nih.gov/pubmed/35303812
http://dx.doi.org/10.1186/s12885-022-09397-4

Ejemplares similares